HCW Biologics公司宣布,其基于IL-2的融合免疫治疗药物HCW9302作为单药疗法,在针对斑秃的1期临床试验中,初步人体数据读出取得了积极成果。
HCW Biologics公司宣布,其基于IL-2的融合免疫治疗药物HCW9302作为单药疗法,在针对斑秃的1期临床试验中,初步人体数据读出取得了积极成果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.